Treatment News : Isentress + Prezista Is Safe, Effective as First-Line HIV Therapy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 19, 2014

Isentress + Prezista Is Safe, Effective as First-Line HIV Therapy

CROI 2014A regimen of Isentress (raltegravir) plus boosted Prezista (darunavir) was comparable in efficacy to a standard treatment with Truvada (tenofovir/emtricitabine) and Prezista in a recent trial, aidsmap reports. As part of the NEAT 001 study, researchers randomly assigned either Isentress or Truvada, pairing both drugs with Prezista, to 805 treatment-naive study participants with HIV. Ninety-six week results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

Seventeen percent of those taking Isentress experienced treatment failure, compared with 14 percent of those on Truvada. Because the difference between these two figures was within a pre-set limit of 9 percent, the Isentress regimen was determined non-inferior, or comparable in efficacy, to the Truvada cocktail. However, those who started therapy with less than 200 CD4 cells did more poorly on Isentress: 39 percent failed therapy, compared with 21 percent who did so on Truvada. The difference was statistically significant—although not very strongly so—meaning it probably did not occur by chance.

To read the aidsmap story, click here.

Search: Isentress, ralegravir, Prezista, darunavir, Truvada, tenofovir, emtricitabine, NEAT 001, Conference on Retrovirus and Opportunistic Infections, CROI.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.